<DOC>
	<DOCNO>NCT02724358</DOCNO>
	<brief_summary>In order provide new option clinical anti-angiogenesis therapy hepatoma , randomize control study plan confirm effect Rg3 combination TACE angiogenesis tumor treatment advance hepatocellular carcinoma patient high expression Notch1 .</brief_summary>
	<brief_title>Rg3 Combination With TACE Hepatocellular Carcinoma Patients With High Expression Notch1</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>1 . Pathologically confirm hepatocellular carcinoma . 2 . High expression Notch1 tumor tissue . pathological evidence HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Hepatocellular</keyword>
	<keyword>Notch1</keyword>
</DOC>